[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Weaver et al., 2016 - Google Patents

Presence of magnetic resonance imaging suspicious lesion predicts Gleason 7 or greater prostate cancer in biopsy-naive patients

Weaver et al., 2016

View PDF
Document ID
1110348182634837427
Author
Weaver J
Kim E
Vetter J
Fowler K
Siegel C
Andriole G
Publication year
Publication venue
Urology

External Links

Snippet

Objective To compare the relative value of magnetic resonance imaging (MRI) in biopsy- naive patients to those with previous negative biopsy. Although MRI-targeted biopsy has been studied in several major prostate cancer (PCa) cohorts (biopsy naive, previous …
Continue reading at drive.google.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences, Generation or control of pulse sequences ; Operator Console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing

Similar Documents

Publication Publication Date Title
Ruprecht et al. MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy
Roethke et al. Evaluation of diffusion kurtosis imaging versus standard diffusion imaging for detection and grading of peripheral zone prostate cancer
Polanec et al. Head-to-head comparison of PI-RADS v2 and PI-RADS v1
Komai et al. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy
Bratan et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study
Sciarra et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy
Boesen et al. Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology
Yagci et al. The value of diffusion-weighted MRI for prostate cancer detection and localization
Scialpi et al. Biparametric MRI of the prostate
Dianat et al. Magnetic resonance–invisible versus magnetic resonance–visible prostate cancer in active surveillance: a preliminary report on disease outcomes
Hamoen et al. Value of serial multiparametric magnetic resonance imaging and magnetic resonance imaging–guided biopsies in men with low-risk prostate cancer on active surveillance after 1 yr follow-up
Mariotti et al. Magnetic resonance/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of prostate cancer: multi-institutional retrospective analysis of 389 patients
Weaver et al. Presence of magnetic resonance imaging suspicious lesion predicts Gleason 7 or greater prostate cancer in biopsy-naive patients
Gaunay et al. Role of multi-parametric MRI of the prostate for screening and staging: Experience with over 1500 cases
Pickersgill et al. The accuracy of prostate magnetic resonance imaging interpretation: impact of the individual radiologist and clinical factors
Zhu et al. Value of quantitative dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging in predicting extramural venous invasion in locally advanced gastric cancer and prognostic significance
Vos et al. Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance
Xiong et al. Value of MRI texture analysis for predicting high-grade prostate cancer
Bladou et al. Transrectal ultrasound-guided biopsy for prostate cancer detection: Systematic and/or magnetic-resonance imaging-targeted
Riney et al. Prostate magnetic resonance imaging: the truth lies in the eye of the beholder
Giganti et al. Magnetic resonance imaging in active surveillance—a modern approach
Lamb et al. Is prebiopsy MRI good enough to avoid prostate biopsy? A cohort study over a 1-year period
Padhani Integrating multiparametric prostate MRI into clinical practice
Kwon et al. Discrimination of local recurrence after radical prostatectomy: value of diffusion-weighted magnetic resonance imaging
Popita et al. 1.5-Tesla Multiparametric-Magnetic Resonance Imaging for the detection of clinically significant prostate cancer